Medexus Pharmaceuticals Holds Annual Meeting and Re-elects Directors

Medexus Pharmaceuticals, a leading pharmaceutical company based in Toronto, Ontario, and Chicago, Illinois, held its virtual annual meeting of shareholders on September 24, 2026. The meeting was significant as it saw the re-election of all nominees listed in the company’s management information circular dated August 10, 2026, as directors. Shareholders also approved the appointment of PricewaterhouseCoopers LLP as the company’s auditors, with 99.560% of the votes cast in favor. Additionally, the shareholders voted in favor of resolutions amending the company’s equity incentive compensation plan, with 94.912% of the votes cast for and 5.088% against.

The voting results for the election of directors are detailed as follows: - All nominees listed in the management information circular dated August 10, 2026, were elected as directors.

The shareholders also cast their votes on the appointment of PricewaterhouseCoopers LLP as the company’s auditors, with the following results: - 13,812,075 (99.560%) votes for - 61,000 (0.440%) votes withheld

For the resolutions amending the company’s equity incentive compensation plan, the voting results were: - 10,906,889 (94.912%) votes for - 584,632 (5.088%) votes against

All proposals were therefore approved by the shareholders. A report of the voting results on all matters voted on at the annual meeting will be filed with Canadian securities regulatory authorities at www.sedarplus.ca.

Medexus Pharmaceuticals is a leading pharmaceutical company with a strong North American commercial platform and a growing portfolio of innovative and rare disease treatment solutions. The company’s current focus is on hematology and hemato-oncology products, including cell and gene therapy products, and historically also on rheumatology and allergy products. For more information about Medexus and its product portfolio, please visit the company’s corporate website at www.medexus.com and its filings on SEDAR+ at www.sedarplus.ca.

This annual meeting underscores the company’s commitment to its shareholders and its ongoing efforts to strengthen its governance and operational framework. The re-election of the board members and the approval of the auditor and equity incentive compensation plan resolutions reflect the confidence of shareholders in the company’s leadership and strategic direction.